Impact of adjuvant pelvic radiotherapy in stage I uterine sarcoma.
Anticancer Res
; 35(1): 365-70, 2015 Jan.
Article
em En
| MEDLINE
| ID: mdl-25550573
ABSTRACT
BACKGROUND/AIM:
The optimal adjuvant therapy for stage I uterine sarcoma remains unresolved and may consist of radiotherapy (RT), chemotherapy, hormonal therapy or observation. We analyzed the impact of adjuvant pelvic RT on overall survival (OS), cause-specific survival (CSS), disease-free survival (DFS), pelvic control (PC) and patterns of failure. PATIENTS ANDMETHODS:
A retrospective analysis of 157 patients with International Federation of Gynecology and Obstetrics FIGO stage I uterine sarcoma was performed. RT was given postoperatively to a dose of 45-51 Gy in 28-30 fractions.RESULTS:
The 5-year OS, CSS, DFS and PC was 58%, 62%, 47% and 72%, respectively. Adjuvant RT significantly improved PC (85% for RT group vs. 64% for non-RT group; p=0.02) but did not impact OS, CSS or DFS.CONCLUSION:
The addition of adjuvant pelvic RT significantly improved PC for patients with stage I uterine sarcoma. As systemic therapies continue to improve, optimal locoregional control may result in improved patient outcomes.Palavras-chave
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Uterinas
/
Carcinossarcoma
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article